tecadenoson

Tecadenoson is a novel, selective A1 adenosine receptor agonist developed for the rapid conversion of paroxysmal supraventricular tachycardia (PSVT) to normal sinus rhythm. Unlike adenosine, which non-selectively stimulates all adenosine receptor subtypes and can cause hypotension and other vasodilatory side effects, tecadenoson selectively targets the A1 adenosine receptor in the atrioventricular (AV) node. This selectivity slows AV nodal conduction without significantly affecting blood pressure or causing common adverse events associated with nonselective adenosine agonists. Clinical studies have shown that intravenous tecadenoson effectively converts PSVT to sinus rhythm with fewer side effects such as flushing, dyspnea, chest discomfort, and hypotension compared to adenosine[1][2][3][5]. Tecadenoson was initially developed by CV Therapeutics and later by Gilead Sciences[1][4].